Pharmafile Logo

News and Press Releases

Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate

Immune response successfully improved with second generation vaccine candidate4 November 2025 -- Saint-Herblain, France -- Valneva SE, a specialty vaccine company, today announced positive results of its Phase 1 clinical...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Delivery, Other, Pharmaceutical
Posted: November 4, 2025

Valneva
communications@valneva.com
6 rue Alain Bombard, 44800 Saint-Herblain, France

Ryvu Therapeutics Announces Three Abstracts on Romaciclib (RVU120) and One Abstract on Dapolsertib (MEN1703) at the 2025 ASH Annual Meeting

Romaciclib continues to show efficacy in AML: Data from the Phase II RIVER-81 trial suggest that romaciclib restores sensitivity to venetoclax in resistant AML, inducing complete remissions with a favorable safety profile Clinical activity in myelofibrosis (MF): Interim results from the Phase II POTAMI-61 study indicate clinically meaningful spleen volume...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 3, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Ryvu Therapeutics Presents RVU305 (PRMT5i) and ONCO Prime Platform Data at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates strong and selective antitumor efficacy in MTAP-deleted glioblastoma models, with confirmed brain exposure and a favorable safety profile supporting IND/CTA-enabling studies...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 27, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Naobios and Tokyo Metropolitan Institute of Medical Science partner to develop new live-attenuated vaccine against mpox

 Partnership aims to commercialize new mpox vaccine - with higher level of safety - by 2027 23 October 2025 -- Nantes, France, and Tokyo, Japan -- Naobios, a CDMO (Contract Development...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 23, 2025

Naobios
Operating office 6 rue Alain Bombard 44800 Saint-Herblain

Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma

Recognizes the potential of HDP-101 to address a serious or life-threatening condition with high unmet medical needs Enables more frequent engagement with FDA and eligibility for rolling review to support...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 23, 2025

Heidelberg Pharma
info@hdpharma.com
Gregor-Mendel-Straße 22 68526 Ladenburg Deutschland

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

Iksuda to present IKS014 Phase 1 data at ESMO

14 October 2025 -- Newcastle, UK -- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs), will present new data from its Phase 1 study of IKS014, a...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 14, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV

Results presented today at ESGCT 2025 10 October 2025 -- Paris, France and Lund, Sweden -- Genethon, a worldwide pioneer and leader in research and development of gene therapy for rare...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 10, 2025

Genethon
1 bis, rue de l’Internationale 91000 EVRY-COURCOURONNES

Relief Therapeutics and NeuroX, Successor to MindMaze, Sign Definitive Agreement for Business Combination

Companies sign definitive agreement following previously announced binding term sheet Transaction to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech company Combined company to be renamed MindMaze Therapeutics Holding...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025

Relief Therapeutics
contact@relieftherapeutics.com
Avenue de Sécheron 15 1202 Geneva Switzerland

Terumo Blood and Cell Technologies Supports Expanded Access to Rare Disease Therapies in Latin America  

Regulatory approvals in 14 countries expand treatment options for sickle cell disease, Guillain-Barré syndrome and myasthenia gravis Approvals align with the historic World Health Assembly resolution on rare diseases. 16...

Category: Biotechnology, Drug Delivery, Other, Pharmaceutical
Posted: September 16, 2025

Terumo Blood and Cell Technologies
Old Belfast Road Millbrook Larne BT40 2SH

PlasmidFactory founder Dr. Martin Schleef honored with the NRW Innovation Award 2025

8 September 2025 -- Düsseldorf/Bielefeld, Germany -- The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored today in Düsseldorf with the Innovation Award 2025 of the...

Category: BioManufacturing, Other, Pharmaceutical
Posted: September 8, 2025

PlasmidFactory GmbH & Co. KG
info@plasmidfactory.com
Meisenstraße 96, D-33607 Bielefeld, Germany

Ryvu Therapeutics Announces Strategic Agreement to Support Clinical Trials for BioNTech’s Investigational Cancer Immunotherapies in Poland

Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clinical programs in Poland Ryvu will leverage its clinical network to...

Category: BioManufacturing, Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: September 2, 2025

Ryvu Therapeutics
ryvu@ryvu.com
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland

Upperton Pharma Solutions Advancing Oral Vaccines Delivery with Oxford’s Pandemic Sciences Institute

14 August 2025 -- Nottingham, UK -- Upperton Pharma Solutions, a leading UK-based contract development and manufacturing organisation (CDMO), has been awarded a grant as part of the first VaxHub Sustainable Platform Funding...

Category: Biotechnology, Drug Delivery, Drug Discovery, Other, Pharmaceutical
Posted: August 14, 2025

Upperton Pharma Solutions
contact@upperton.com
Albert Einstein Centre, Nottingham Science Park, Nottingham, UK, NG7 2TN

Iksuda Therapeutics receives FDA IND clearance for IKS014

FDA decision will enable Iksuda to expand its ongoing clinical trial in the US, Australia and Singapore Preliminary data from an ongoing dose-escalation study of IKS014 has shown meaningful clinical activity across...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 1, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Sanner starts manufacturing in Greensboro, USA

18 June 2025 -- North Carolina, US -- Sanner has officially launched manufacturing operations in Greensboro, North Carolina. The new facility is dedicated to producing critical injection-molded components for medical...

Category: Logistics, Manufacturing and Packing, Other, Pharmaceutical, Pharmaceutical Contractors
Posted: June 18, 2025

Sanner
info@sanner-group.com
Schillerstrasse 76 64625 Bensheim